United States (National)
Not enough data
Benjamin P. Levy's coverage prominently focuses on healthcare and pharmaceuticals, particularly in the context of cancer treatment with a specific emphasis on NSCLC (non-small cell lung cancer), antibody-drug conjugates, biomarker testing, and gastric cancer.
Given this focus, he is likely to be most responsive to pitches that offer expert commentary from professionals deeply involved in the development or application of oncology treatments such as researchers, clinicians specializing in lung cancer treatment, pharmaceutical industry experts or patient advocates.
As Benjamin’s articles cite data extensively and delve into industry-specific details related to healthcare and biotechnology topics like clinical trials or drug developments, tailored pitches offering new research findings or insights into emerging treatments are more likely to resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Benjamin P. Levy, Siddhartha Devarakonda, D. Ross Camidge, Julia K. Rotow, Gilberto Lopes
Dr. Rotow discusses limitations of traditional CTCAE toxicity grading for capturing patient experiences with EGFR-targeted therapies. Although useful for discrete, measurable, and life-threatening toxicities, CTCAE poorly captures lower-grade effects like skin rash or fatigue that significantly impact quality of life over extended treatment periods.
By: Benjamin P. Levy, Ross Camidge, Julia K. Rotow, Siddhartha Devarakonda, Gilberto Lopes
Dr. Camidge characterizes amivantamab as more time-intensive and supportive care-intensive, believing it represents a more toxic regimen than FLAURA-2 despite optimal supportive measures.
By: Julia K. Rotow, Gilberto Lopes, Siddhartha Devarakonda, Benjamin P. Levy, Ross Camidge
The subcutaneous formulation reduces infusion-related reactions from 60% to 20%, though Dr. Camidge notes that 20% still represents an unacceptably high rate for a new regimen.
By: Siddhartha Devarakonda, Ross Camidge, Julia K. Rotow, Gilberto Lopes, Benjamin P. Levy
Historical recognition of TP53 as an adverse prognostic factor lacked actionable interventions until frontline combinations became available.
By: Kevin Beiner, Robert Garrett, Deepak L. Bhatt, Stephanie Wierwille, Benjamin P. Levy
In the third video in our series, our panel talks about the need to lower the cost of care for patients, and growing pressures on their operating margins.
By: Benjamin P. Levy, Kevin Beiner, Stephanie Wierwille, Deepak L. Bhatt, Robert Garrett
In the second video from our roundtable, the panel discusses delivering more care outside of the hospital, the emerging opportunities for AI, and the need for thoughtful strategies.
By: Kevin Beiner, Robert Garrett, Deepak L. Bhatt, Stephanie Wierwille, Benjamin P. Levy
With 2026 as a genuine crossroads for healthcare leadership, our panel talks about the issues at the top of their minds.
By: Julia K. Rotow, Ross Camidge, Benjamin P. Levy, Siddhartha Devarakonda, Gilberto Lopes
Both liquid and tissue biopsies have roles in progression workup. Liquid biopsies offer rapid turnaround but cannot be trusted when negative due to false-negative rates.
By: Ross Camidge, Siddhartha Devarakonda, Gilberto Lopes, Julia K. Rotow, Benjamin P. Levy
Dr. Lopes analyzes the evidence hierarchy, noting stronger evidence for MARIPOSA-2 with over 600 patients in a fully-powered study versus COMPEL's under 100 patients in an early-stopped trial.
By: Robert Garrett, Benjamin P. Levy, Deepak L. Bhatt, Kevin Beiner, Stephanie Wierwille
In the latest video from our roundtable, healthcare leaders talk about the impact of insufficient reimbursements. They're posing more headaches for hospitals and affecting patient care, the panel says.
